KR102862077B1 - 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체 - Google Patents

인간화 항-n-절단 아밀로이드 베타 단일 클론 항체

Info

Publication number
KR102862077B1
KR102862077B1 KR1020217012796A KR20217012796A KR102862077B1 KR 102862077 B1 KR102862077 B1 KR 102862077B1 KR 1020217012796 A KR1020217012796 A KR 1020217012796A KR 20217012796 A KR20217012796 A KR 20217012796A KR 102862077 B1 KR102862077 B1 KR 102862077B1
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217012796A
Other languages
English (en)
Korean (ko)
Other versions
KR20210080400A (ko
Inventor
토마스 바이어
프레티 바카라니아
사라 다비에스
알렉스 브라운
차이도우 엠파마가
데이비드 매튜스
마크 카아
그레스 할
Original Assignee
게오르그-아우구스트-우니베시태트 괴팅겐 스티프퉁 외펜틀리헨 레흐츠, 우니베시태츠메디진
라이프아크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게오르그-아우구스트-우니베시태트 괴팅겐 스티프퉁 외펜틀리헨 레흐츠, 우니베시태츠메디진, 라이프아크 filed Critical 게오르그-아우구스트-우니베시태트 괴팅겐 스티프퉁 외펜틀리헨 레흐츠, 우니베시태츠메디진
Publication of KR20210080400A publication Critical patent/KR20210080400A/ko
Application granted granted Critical
Publication of KR102862077B1 publication Critical patent/KR102862077B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217012796A 2018-10-04 2019-10-02 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체 Active KR102862077B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816210.7 2018-10-04
GB201816210 2018-10-04
PCT/EP2019/076772 WO2020070225A1 (en) 2018-10-04 2019-10-02 Humanised anti-n-truncated amyloid beta monoclonal antibody

Publications (2)

Publication Number Publication Date
KR20210080400A KR20210080400A (ko) 2021-06-30
KR102862077B1 true KR102862077B1 (ko) 2025-09-18

Family

ID=68136417

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217012796A Active KR102862077B1 (ko) 2018-10-04 2019-10-02 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체

Country Status (13)

Country Link
US (1) US12297261B2 (https=)
EP (1) EP3861023A1 (https=)
JP (1) JP7610515B2 (https=)
KR (1) KR102862077B1 (https=)
CN (1) CN113056480B (https=)
AU (1) AU2019354714A1 (https=)
BR (1) BR112021006153A2 (https=)
CA (1) CA3114669A1 (https=)
EA (1) EA202190954A1 (https=)
IL (1) IL281979B2 (https=)
MX (1) MX2021003867A (https=)
SG (1) SG11202102765RA (https=)
WO (1) WO2020070225A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4118111A1 (en) 2020-03-10 2023-01-18 LifeArc Cyclic peptides
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167681A1 (en) 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
WO2017009459A2 (en) 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474900A (en) 1892-05-17 William byrnes
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO2008081008A1 (en) * 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
MY155144A (en) 2007-10-29 2015-09-15 Inst Nat Sante Rech Med NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2015173133A1 (en) 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP4118111A1 (en) * 2020-03-10 2023-01-18 LifeArc Cyclic peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167681A1 (en) 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
WO2017009459A2 (en) 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies

Also Published As

Publication number Publication date
CA3114669A1 (en) 2020-04-09
JP7610515B2 (ja) 2025-01-08
BR112021006153A2 (pt) 2021-06-29
MX2021003867A (es) 2021-09-08
JP2022513331A (ja) 2022-02-07
EA202190954A1 (ru) 2021-06-29
US20210347867A1 (en) 2021-11-11
EP3861023A1 (en) 2021-08-11
CN113056480A (zh) 2021-06-29
AU2019354714A1 (en) 2021-04-29
SG11202102765RA (en) 2021-04-29
IL281979B2 (en) 2025-09-01
KR20210080400A (ko) 2021-06-30
US12297261B2 (en) 2025-05-13
IL281979B1 (en) 2025-05-01
IL281979A (en) 2021-05-31
CN113056480B (zh) 2025-06-13
US20230203140A9 (en) 2023-06-29
WO2020070225A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
JP7410143B2 (ja) 二重特異性抗体及びその用途
US11981730B2 (en) Anti-CXCL13 antibodies and methods of using the same
TWI754157B (zh) 抗ｔｉｇｉｔ抗體及其用途
KR102862077B1 (ko) 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
EP2451842B1 (en) Humanised antibodies to toll-like receptor 2 and uses thereof
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
JP2010518873A (ja) アンタゴニスト抗ｏｘ４０抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
KR20230009441A (ko) 항-tigit 항체, 이의 제조 방법 및 용도
JP2019524052A (ja) ＦｃγＲＩＩＡに特異的な結合分子及びその使用
US20240026009A1 (en) Antibodies to galectin-3 and methods of use thereof
TW201942135A (zh) 抗cd27 抗體、其抗原結合片段及其醫藥用途
JP2025041747A (ja) ヒト化抗ｉｌ１７ｂｒ抗体
TW202304985A (zh) 治療性結合分子
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
TW202222830A (zh) 貓抗體變異體
CN119630702A (zh) Klrb1结合剂及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)